anti-nicotine antibody gene therapy (Weill Cornell Medical College/Scripps Research Institute)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-nicotine antibody gene therapy (Weill Cornell Medical College/Scripps Research Institute)

Drug Alias NameAAVrh.10antiNic.Mab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector

Mechanisms of ActionImmunostimulants

TargetsUpdating

Therapy Area/IndicationsTobacco Use Disorder

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesThe Scripps Research Institute Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesWeill Medical College of Cornell University The Scripps Research Institute Inc

Active IndicationsN/A

Inactive IndicationsTobacco Use Disorder

Other Information

ATC CodeN/A